top of page
The Professional Network for Healthcare Experts
Italfarmaco licenses JCR's Phase III Hunter syndrome therapy JR-141 across US, Europe and Latin America
Italfarmaco has licensed JCR Pharmaceuticals' Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America.
nuaxia
9 hours ago2 min read
Genentech licenses Alector brain-penetrant Parkinson's programme in deal worth up to $1.27bn
Genentech has licensed Alector's brain-penetrant AL050 programme in a neurodegeneration deal worth up to $1.27 billion.
nuaxia
1 day ago2 min read
bottom of page